Deutsche Bank Aktiengesellschaft Boosts Elevance Health (NYSE:ELV) Price Target to $363.00

Elevance Health (NYSE:ELV) had its price objective boosted by analysts at Deutsche Bank Aktiengesellschaft from $332.00 to $363.00 in a research note issued on Thursday,MarketScreener reports. The brokerage presently has a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 5.33% from the stock’s previous close.

ELV has been the topic of several other research reports. The Goldman Sachs Group increased their price target on Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a report on Friday. Leerink Partners set a $364.00 price target on Elevance Health in a report on Thursday. Guggenheim increased their price target on Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a report on Friday. UBS Group set a $400.00 price objective on shares of Elevance Health in a research note on Thursday, January 29th. Finally, Wells Fargo & Company decreased their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Eleven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Elevance Health has a consensus rating of “Hold” and a consensus price target of $380.42.

Elevance Health Stock Performance

NYSE:ELV opened at $344.64 on Thursday. The stock’s fifty day moving average is $308.96 and its 200 day moving average is $331.62. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $427.54. The firm has a market capitalization of $74.84 billion, a PE ratio of 14.66, a PEG ratio of 1.84 and a beta of 0.49. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.48.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same quarter in the prior year, the firm posted $11.97 EPS. Elevance Health’s quarterly revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, sell-side analysts anticipate that Elevance Health will post 26.79 earnings per share for the current year.

Institutional Trading of Elevance Health

Institutional investors have recently added to or reduced their stakes in the company. Murphy Middleton Hinkle & Parker Inc. purchased a new stake in shares of Elevance Health in the 4th quarter worth $5,941,000. Evergreen Wealth Management LLC lifted its holdings in shares of Elevance Health by 33.5% in the 3rd quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after buying an additional 4,336 shares during the period. Blume Capital Management Inc. lifted its holdings in shares of Elevance Health by 236.7% in the 3rd quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock worth $1,986,000 after buying an additional 4,320 shares during the period. Canoe Financial LP lifted its holdings in shares of Elevance Health by 18.1% in the 3rd quarter. Canoe Financial LP now owns 389,399 shares of the company’s stock worth $125,823,000 after buying an additional 59,743 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in shares of Elevance Health by 31.1% in the 3rd quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock worth $149,182,000 after buying an additional 109,462 shares during the period. Institutional investors own 89.24% of the company’s stock.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 beat and upgraded outlook — ELV reported strong Q1 results (EPS $12.58 vs. estimates) and raised its 2026 adjusted EPS outlook to at least $26.75 while targeting ~12% EPS growth in 2027, which supports earnings upside and margin improvement. Elevance raises 2026 outlook
• Positive Sentiment: Large analyst upgrade — Sanford C. Bernstein raised its price target to $424 and kept an “outperform” rating, implying ~23% upside; a high-conviction bullish call that can attract demand. Bernstein raises PT to $424
• Positive Sentiment: Barclays reiteration of Buy — Barclays stuck with a Buy rating, signaling institutional confidence that can provide support for the shares. Barclays sticks to Buy
• Positive Sentiment: Operational tailwinds noted — Management highlighted medical cost controls and AI-driven margin expansion, and major outlets reported the company raised its annual profit forecast on those controls, reinforcing the positive earnings message. Profit forecast raised on cost controls
• Neutral Sentiment: Mixed analyst PT lifts with conservative ratings — Several firms nudged up targets but kept neutral/hold stances (Goldman to $370 neutral; Deutsche Bank to $363 hold; Evercore to $360 in-line). These raise reference prices but signal measured optimism. Goldman raises PT to $370
• Neutral Sentiment: Jefferies update — Jefferies revised its forecasts after a deeper look at exchange-segment dynamics and trimmed its PT slightly; this is an analyst reshuffle rather than a directional shock. Jefferies updates forecasts
• Negative Sentiment: Investor litigation probe — Law firm Kirby McInerney has opened an investigation into potential securities claims involving Elevance and/or its senior management; legal scrutiny can pressure the stock and raise uncertainty. Kirby McInerney investor alert
• Negative Sentiment: Some broker nuance implies limited near-term upside — Robert W. Baird’s update leaves a neutral stance with a lower relative target vs. some peers, noting limited immediate upside which can cap buying interest. Baird adjusts PT

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.